All Episodes – Page 7

An interview with: Ajay Goel PhD, Chair of the Molecular Diagnostics and Experimental Therapeutics Department, Beckman Research Institute, City of Hope, Los Angeles California.  SAN DIEGO—The prospect

An interview with: Sundar Jagannath MBBS, Professor of Medicine, Hematology and Medical Oncology, Director of the Center of Excellence for Multiple Myeloma, Icahn School of Medicine, Mount Sinai, New

An interview with: Olivier Lantz MD PhD, Head of the Clinical Immunology Laboratory, Institut Curie, Paris, France PARIS, France—A clinical trial using a personalized therapeutic vaccine, that

SAN ANTONIO, USA—Women with hormone receptor positive HER-2 negative breast cancer and Oncotype DX recurrence scores above 31 could benefit from having anthracycline therapy added to their taxane-base

SAN FRANCISCO, CA—Adding the poly ADP ribose polymerase (PARP) inhibitor drug talazoparib to standard anti-androgen therapy with enzalutamide statistically significantly extended overall survival amon

Audio Journal of Oncology Patients with Desmoplastic Melanoma Were Exceptional Responders to Single Agent Pembrolizumab LOS ANGELES, CA—Single agent immunotherapy with the anti-programmed death-1 (PD-

Bilateral Mastectomy and Salpingo-Oophorectomy Significantly Extend Survival In BRCA-mutation Carriers Who Already Have Breast Cancer The important question of whether to recommend risk-reducing surge

SAN ANTONIO, USA—In patients with hormone receptor-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS) active monitoring, compared with surgery, resulted in no difference in terms of can

SAN ANTONIO, USA—There was no benefit from chest wall irradiation in patients who had intermediate-risk breast cancer, according to findings reported at the 2024 San Antonio Breast Cancer Symposium fr

SAN DIEGO, USA—When added to standard chemotherapy the bi-specific T-cell engager drug blinatumomab brought a large, statistically significant improvement in disease-free survival in a randomized cont

Audio Journal of Oncology Podcast December, 2024: Double-Edged CAR-T Therapy Improves Survival with Relapsed/Refractory Chronic Lymphoblastic Leukemia Hua Zhang MD PhD (Chief Scientific Officer with S

BRIGHTON, UK—In underserved communities throughout the world low rates of early breast cancer detection are key drivers of mortality, according to the findings of research from Uganda, the United King

Amy A. Kirkwood MSc

Don't Delay Stem Cell Transplant For Patients with Relapsed or Refractory Acute Myeloid Leukemia

Ibrutinib Enables Transplant-Free Therapy for Mantle Cell Lymphoma NEW ORLEANS, USA—Many patients eligible for autologous stem cell transplantation for their mantle cell lymphoma (under current best p

January 10, 2023 Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma INTERVIEW WITH: Ajai Chari MD, Associate Professor of Medicine and Director of Clinical

An interview with: Byoung Chul Cho MD PhD, Thoracic Medical Oncologist, from the Yonsei Cancer Center at Yonsei University College of Medicine in Seoul, South Korea. BARCELONA, Spain—A “next gen

ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine

Pan-AKT Inhibitor Tumor Agnostic Targeting  was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT i

BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and